Public source
Reviewed 21 Jul 2026
Completeness Fair (31%)
The uPath PD-L1 (SP263) image analysis, NSCLC algorithm is an adjunctive computer-assisted tool that identifies PD-L1 negative and positive tumor cells within a pathologist-annotated viable tumor region in images of formalin-fixed, paraffin-embedded neoplastic lung tissue.
Supported by 3 papers
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Not specified
Staining
Stain subtype
Not specified
Regulatory Information
Pathway:
In Vitro Diagnostic Directive (IVDD)
Class:
General IVD Devices
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Evidence & Research
Peer-Reviewed Papers
Comparative performance of <scp>PD</scp>‐<scp>L1</scp> scoring by pathologists and <scp>AI</scp> algorithms
Histopathology · Feb 2025
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade
Pathologica · Oct 2024
Machine-learning-based image analysis algorithms improve interpathologist concordance when scoring PD-L1 expression in non-small-cell lung cancer
Journal of Clinical Pathology · Dec 2023
Technical Specifications
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Population
Not specified
Viewer systems
Not specified
Market Presence
On market since
Not specified
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Source: Public | First published: Apr 22, 2026 | Last updated: Jul 21, 2026